Gland Pharma Receives Approval for Angiotensin II Acetate Injection

Gland Pharma Limited (Gland or Company), a generic injectable & ophthalmicfocused pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Angiotensin II Acetate Injection 2.5 mg/mL.

The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), GIAPREZA® of La Jolla Pharma LLC.

This Product is indicated for increasing the blood pressure in adults with septic or other distributive shock.

Gland Pharma is the exclusive First-to-File and is eligible for 180 days of generic drug exclusivity.

According to IQVIA, the product had US sales of approximately USD 58 million for the twelve months ending March 2025.

Shares of Gland Pharma Limited was last trading in BSE at Rs. 1630.10 as compared to the previous close of Rs. 1623.70. The total number of shares traded during the day was 8511 in over 705 trades.

The stock hit an intraday high of Rs. 1639.00 and intraday low of 1608.45. The net turnover during the day was Rs. 13831771.00.

Source : Equity Bulls

Keywords

GlandPharma INE068V01023 Pharmaceuticals Approval USFDA ANDA AngiotensinIIAcetate Injection